324 related articles for article (PubMed ID: 30347405)
1. The American Joint Commission Cancer 8th Edition Prognostic Stage Including Oncotype DX® Recurrence Score: Impact on Staging of Early Breast Cancer.
O'Cearbhaill R; Gannon JM; Prichard RS; Walshe JM; McDermott E; Quinn CM
Pathobiology; 2019; 86(2-3):77-82. PubMed ID: 30347405
[TBL] [Abstract][Full Text] [Related]
2. Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.
Breaux A; Turner B; Wu X; Rai SN; Riley EC; Mandadi M; Sanders MA
Clin Breast Cancer; 2019 Feb; 19(1):e261-e269. PubMed ID: 30509870
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
4. The comparison of the anatomic stage and pathological prognostic stage according to the AJCC 8th edition for the prognosis in Japanese breast cancer patients: data from a single institution.
Tokunaga E; Ijichi H; Tajiri W; Masuda T; Takizawa K; Ueo H; Koga C; Tanaka J; Nakamura Y; Ohno S; Taguchi K; Okamoto M
Breast Cancer; 2020 Nov; 27(6):1137-1146. PubMed ID: 32472474
[TBL] [Abstract][Full Text] [Related]
5. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
6. Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system.
Yoon EC; Schwartz C; Brogi E; Ventura K; Wen H; Darvishian F
Breast J; 2019 Sep; 25(5):829-837. PubMed ID: 31197914
[TBL] [Abstract][Full Text] [Related]
7. The Added Prognostic Value of Oncotype Recurrence Score to AJCC Prognostic Staging System in Stage III ER+/HER2- Breast Cancer.
Wang M; Zhang M; Chen H
Adv Ther; 2023 Sep; 40(9):3912-3925. PubMed ID: 37382865
[TBL] [Abstract][Full Text] [Related]
8. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
9. The assessment of 8th edition AJCC prognostic staging system and a simplified staging system for breast cancer: The analytic results from the SEER database.
Zhang J; Zhao B; Jin F
Breast J; 2019 Sep; 25(5):838-847. PubMed ID: 31192530
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis.
Ding S; Wu J; Lin C; Andriani L; Goh C; Chen W; Li Y; Shen K; Zhu L
Oncologist; 2019 Nov; 24(11):e1014-e1023. PubMed ID: 31019021
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.
Yorozuya K; Takeuchi T; Yoshida M; Mouri Y; Kousaka J; Fujii K; Nakano S; Fukutomi T; Hara K; Ichihara S; Lin Y; Kikuchi S
J Cancer Res Clin Oncol; 2010 Jun; 136(6):939-44. PubMed ID: 19946706
[TBL] [Abstract][Full Text] [Related]
13. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
14. Evaluation oncotype DX
Lashen A; Toss MS; Fadhil W; Oni G; Madhusudan S; Rakha E
Histopathology; 2023 Apr; 82(5):755-766. PubMed ID: 36631400
[TBL] [Abstract][Full Text] [Related]
15. Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage.
Koh J; Kim MJ
Korean J Radiol; 2019 Jan; 20(1):69-82. PubMed ID: 30627023
[TBL] [Abstract][Full Text] [Related]
16. Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
Vissio E; Metovic J; Osella-Abate S; Bertero L; Migliaretti G; Borella F; Benedetto C; Sapino A; Cassoni P; Castellano I
Br J Cancer; 2020 Feb; 122(3):382-387. PubMed ID: 31780778
[TBL] [Abstract][Full Text] [Related]
17. Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort.
Kim JY; Lim JE; Jung HH; Cho SY; Cho EY; Lee SK; Yu JH; Lee JE; Kim SW; Nam SJ; Park YH; Ahn JS; Im YH
Breast Cancer Res Treat; 2018 Oct; 171(3):737-745. PubMed ID: 29931426
[TBL] [Abstract][Full Text] [Related]
18. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Giuliano AE; Connolly JL; Edge SB; Mittendorf EA; Rugo HS; Solin LJ; Weaver DL; Winchester DJ; Hortobagyi GN
CA Cancer J Clin; 2017 Jul; 67(4):290-303. PubMed ID: 28294295
[TBL] [Abstract][Full Text] [Related]
19. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Auerbach J; Kim M; Fineberg S
Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC; Miller DP; Shak S; Petkov VI
Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
